Temsirolimus: CCI 779, CCI-779, Cell Cycle Inhibitor-779

By Adis International Limited  

Drugs in R&D, Vol. 5, Iss. 6, 2004-01 ,pp. : 363-367

Adis International

Access to resources Recommend Favorite

Gemcitabine plus capecitabine has modest activity in the treatment of metastatic renal cancer refractory to or unsuitable for immunotherapy

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Management of Metastatic Renal Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 1, 2005-01 ,pp. : 105-113

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

By Chang Susan   Wen Patrick   Cloughesy Timothy   Greenberg Harry   Schiff David   Conrad Charles   Fink Karen   Robins H.   Angelis Lisa   Raizer Jeffrey   Hess Kenneth   Aldape Ken   Lamborn Kathleen   Kuhn John   Dancey Janet   Prados Michael  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 357-361

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate   Keam Susan J.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite